AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19761536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough-reflex sensitivity evaluated using log concentration of capsaicin causing five or more coughs (log C(5)) in COPD patients.
Number of subjects: 45
Study 19761536 — intervention group
Group type: COMPARATOR
Intervention: Cough-reflex sensitivity evaluated using log concentration of capsaicin causing five or more coughs (log C(5)) in control group.
Number of subjects: 45
Study 17992451 — intervention group
Group type: COMPARATOR
Intervention: UVB monotherapy
Number of subjects: 193
Study 17992451 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB + bergamot oil (UVBB)
Number of subjects: 193
Study 15990127 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension clinic
Number of subjects: 51
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-submerged ITI implants
Number of subjects: 233
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: First 498 implants after at least five years of functional loading
Number of subjects: 233
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mm long implants
Number of subjects: 233
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mm long implants
Number of subjects: 233
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mm long implants
Number of subjects: 233
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implants
Number of subjects: 233
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary implants
Number of subjects: 233
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with both maxillary and mandibular prostheses
Number of subjects: 233
Study 12010156 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants supporting maxillary overdentures retained by Dolder bars
Number of subjects: 233
Study 10458050 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 16
Study 10458050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7821124 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK-receptor antagonist)
Number of subjects: 26
Study 7821124 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 26
Study 1695053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin) given once daily
Number of subjects: 96
Study 1695053 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 96
Study 1695053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin)
Number of subjects: 96
Study 76748 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (E.C.T.)
Number of subjects: 40
Study 76748 — intervention group
Group type: COMPARATOR
Intervention: Simulated E.C.T.
Number of subjects: 40
Study 31132157 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28982045 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 212
Study 28982045 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 212
Study 26476943 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plane of milk replacer nutrition (28% CP, 20% fat) with human visitation (A1)
Number of subjects: 36
Study 26476943 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plane of milk replacer nutrition (28% CP, 20% fat) without human visitation (A0)
Number of subjects: 36
Study 26476943 — intervention group
Group type: COMPARATOR
Intervention: Conventional milk replacer (20% CP, 20% fat) with human visitation (C1)
Number of subjects: 36
Study 26476943 — intervention group
Group type: COMPARATOR
Intervention: Conventional milk replacer (20% CP, 20% fat) without human visitation (C0)
Number of subjects: 36
Study 26476943 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plane of milk replacer nutrition (A0 and A1)
Number of subjects: 36
Study 26476943 — intervention group
Group type: EXPERIMENTAL
Intervention: Human visitation
Number of subjects: 36
Study 26476943 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plane of nutrition (A0 and A1)
Number of subjects: 36
Study 23775260 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 2 mg
Number of subjects: 201
Study 23775260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 21255856 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided soccer games on badminton court (6.1×13.4 m)
Number of subjects: 12
Study 21255856 — intervention group
Group type: COMPARATOR
Intervention: Small-sided soccer games on volleyball court (9×18 m)
Number of subjects: 12
Study 21255856 — intervention group
Group type: COMPARATOR
Intervention: Small-sided soccer games on basketball court (14.2×26.5 m)
Number of subjects: 12
Study 20037706 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone hexacetonide combined with 15 mCi Samarium(153)‐particulate hydroxyapatite (Sm/TH group)
Number of subjects: 58
Study 20037706 — intervention group
Group type: COMPARATOR
Intervention: 40 mg triamcinolone hexacetonide alone (TH group)
Number of subjects: 58
Study 17696821 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic drugs
Number of subjects: 0
Study 15151687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education programme (yearly 1-h instruction)
Number of subjects: 3291
Study 15151687 — intervention group
Group type: COMPARATOR
Intervention: Control group (676 12-year-old children, no intervention)
Number of subjects: 3291
Study 12359855 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid at 4 mg
Number of subjects: 643
Study 12359855 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid at 8/4 mg
Number of subjects: 643
Study 12359855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 12359855 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid at 4 mg and 8/4 mg
Number of subjects: 643
Study 9537491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Neurological Inventory (NNI)
Number of subjects: 106
Study 9537491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobiological Risk Score (NBRS)
Number of subjects: 106
Study 9537491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational Age Factor (GAF) and Auditory Evoked Response Factor (AERF)
Number of subjects: 106
Study 9537491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular Haemorrhage (IVH) and Bilirubin levels
Number of subjects: 106
Study 9537491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular Haemorrhage (IVH) and Assisted Ventilation
Number of subjects: 106
Study 8076871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' consultations
Number of subjects: 706
Study 8076871 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 706
Study 2644876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 28
Study 2644876 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 28
Study 1155918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisomicin
Number of subjects: 0
Study 1155918 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (2 mg/kg)
Number of subjects: 0
Study 31787410 — intervention group
Group type: EXPERIMENTAL
Intervention: Conspicuous messaging (highlighting the amount of rewards)
Number of subjects: 50286
Study 31787410 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic messaging (promoting vaccinations with no mention of rewards)
Number of subjects: 50286
Study 31787410 — intervention group
Group type: COMPARATOR
Intervention: No-message control
Number of subjects: 50286
Study 30205184 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated personalized diabetes management (iPDM)
Number of subjects: 907
Study 30205184 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 907
Study 28683960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite
Number of subjects: 98
Study 28683960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 26265109 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming blanket plus prewarmed intravenous (i.v.) infusion
Number of subjects: 0
Study 26265109 — intervention group
Group type: COMPARATOR
Intervention: Only blanket (blanket group)
Number of subjects: 0
Study 26265109 — intervention group
Group type: COMPARATOR
Intervention: Blanket plus electric blanket (heating blanket group)
Number of subjects: 0
Study 22841432 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine (EPI100)
Number of subjects: 60
Study 22841432 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 epinephrine (EPI200)
Number of subjects: 60
Study 20189775 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg every 12h for 5 days
Number of subjects: 391
Study 20189775 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 225 mg every 12h for 5 days
Number of subjects: 391
Study 20189775 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 450 mg every 12h for 5 days
Number of subjects: 391
Study 20189775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 20054189 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate and 1‐(OH)‐vitamin D supplementation
Number of subjects: 40
Study 20054189 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 40
Study 16844725 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech pathology intervention
Number of subjects: 87
Study 16844725 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 87
Study 12950861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (HES 70/0.5)
Number of subjects: 64
Study 12950861 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 64
Study 10812285 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 14
Study 10812285 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (7.5 mg)
Number of subjects: 14
Study 10812285 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (15 mg)
Number of subjects: 14
Study 10812285 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (0 mg)
Number of subjects: 14
Study 10812285 — intervention group
Group type: COMPARATOR
Intervention: THC (0 mg)
Number of subjects: 14
Study 8684686 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO (4000 IU/ml, subcutaneous treatment on alternate days)
Number of subjects: 24
Study 1904892 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label drug titration (nonrandomized patients)
Number of subjects: 318
Study 1904892 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo therapy (control group)
Number of subjects: 318
Study 6352602 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin plus tobramycin
Number of subjects: 0
Study 6352602 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin plus placebo
Number of subjects: 0
Study 6352602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus tobramycin
Number of subjects: 0
Study 30738645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (campaign on influenza vaccination)
Number of subjects: 32
Study 30738645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 29171848 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-epicatechin (30 mg per day for 7 days)
Number of subjects: 0
Study 29171848 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-epicatechin (incremental doses of 10, 30 or 100 mg)
Number of subjects: 0
Study 29171848 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-epicatechin (0.003, 0.01, 0.03, 0.1 and 0.3 mg kg-1 day-1 for 2 weeks)
Number of subjects: 0
Study 29171848 — intervention group
Group type: COMPARATOR
Intervention: +catechin (0.1 mg kg-1 day-1)
Number of subjects: 0
Study 29231495 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (empirical ten needles, thirteen needles of the governor vessel, twelve needles of hand and foot, and symptomatic points)
Number of subjects: 42
Study 29231495 — intervention group
Group type: COMPARATOR
Intervention: Shallow needling therapy (at sites 0.2 to 0.3 cun lateral to the acupoints, no qi arrival required)
Number of subjects: 42
Study 29231495 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 42
Study 29231495 — intervention group
Group type: COMPARATOR
Intervention: Shallow needling therapy
Number of subjects: 42
Study 25588685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation effectiveness quotient (AEQ) calculated from post-AFA levels of serum high sensitivity cardiac troponin T (HScTnT) and duration of RF application
Number of subjects: 60
Study 25588685 — intervention group
Group type: EXPERIMENTAL
Intervention: AEQ >0.4 ng/L/s in patients with paroxysmal AF
Number of subjects: 60
Study 23218907 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation education
Number of subjects: 60
Study 23218907 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional classroom teaching + Simulation education
Number of subjects: 60
Study 23218907 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom teaching
Number of subjects: 60
Study 20081548 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative fluid minihysteroscopy with low pressure saline uterine distention
Number of subjects: 140
Study 20081548 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative hysteroscopy)
Number of subjects: 140
Study 20081548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 18160551 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation-assisted training
Number of subjects: 5
Study 18160551 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation-unassisted training
Number of subjects: 5
Study 18160551 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation training
Number of subjects: 5
Study 18160551 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5
Study 16636540 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP >162.2 pmol/l
Number of subjects: 219
Study 16636540 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP levels in the highest quartile (> or =162.2 pmol/l)
Number of subjects: 219
Study 16636540 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP
Number of subjects: 219
Study 12559795 — intervention group
Group type: EXPERIMENTAL
Intervention: IM high dose hepatitis B virus (HBV) vaccine
Number of subjects: 60
Study 12559795 — intervention group
Group type: COMPARATOR
Intervention: IM standard dose HBV vaccine plus granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 60
Study 12559795 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose HBV vaccine plus GM‐CSF
Number of subjects: 60
Study 10800019 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise program
Number of subjects: 16
Study 10800019 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 8987040 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 ug/kg
Number of subjects: 45
Study 8987040 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 ug/kg
Number of subjects: 45
Study 8987040 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 45
Study 8427660 — intervention group
Group type: COMPARATOR
Intervention: Magnesium supplementation (15 mmol Mg2+/day for 3 weeks, followed by 30 mmol Mg2+/day for another 3 weeks, finishing with 40 mmol Mg2+/day for a final 3 weeks)
Number of subjects: 17
Study 3318723 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg methylprednisolone infusion
Number of subjects: 21
Study 3318723 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g methylprednisolone infusion
Number of subjects: 21
Study 3318723 — intervention group
Group type: COMPARATOR
Intervention: Control group (unspecified alternative therapy)
Number of subjects: 21
Study 30665819 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening for low thoracic bone mineral density (BMD) using quantitative CT (QCT) software
Number of subjects: 1487
Study 29059108 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES + STSTS
Number of subjects: 63
Study 29059108 — intervention group
Group type: EXPERIMENTAL
Intervention: STSTS only
Number of subjects: 63
Study 29059108 — intervention group
Group type: COMPARATOR
Intervention: NAT
Number of subjects: 63
Study 26153378 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline irrigation after myringotomy
Number of subjects: 536
Study 26153378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin three times a day for 7 days postoperatively
Number of subjects: 536
Study 26153378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin plus topical ciprofloxacin drops (4 drops three times a day for 3 days)
Number of subjects: 536
Study 26153378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 536